

## Supplementary Table S1

### European Survey for Thoracic Pathologists

#### *Practice during the COVID-19 Pandemic*

#### I. Biosafety procedures

##### Since the 15<sup>th</sup> of March 2020 until now:

- What type of hood did you use for gross macroscopy of fresh and/or frozen sections from specimens of the lungs?

*Select an answer*, if another type of hood, please clarify: *Select an answer*

- For gross macroscopy of fresh and/or frozen sections from lungs, were you working on a:

*Select an answer*, if another environment, please clarify:

- How many people were allowed to work at the same time in the macroscopy room?

- Did you have a specific room for fresh specimen/frozen section gross macroscopy and another room for gross macroscopy of fixed specimens?  Yes  No

- For cytological specimens, did you work with *Select an answer*, if another, please clarify:

- If you have pneumatic tubes:

- Did you stop all specimen transfer after the 15<sup>th</sup> of March?  Yes  No

- Did you stop transfer later? Please provide the date *provide the date*.

- Do you still use pneumatic tubes for thoracic surgical specimens?  Yes  No

- Did you stop transfer unless the patient was known to be COVID-19 negative?  Yes  No

- Concerning the transport by hospital couriers of samples to the pathology laboratory:

- Did they bring samples in a triple package?  Yes  No

- Did they bring samples as usual?  Yes:  No

- Concerning the PPE (protective personal equipment). Did the personal (technician & pathologist) wear?

- Mask: *Select an answer*

- Glove: *Select an answer*

Surgical cap

Surgical overshoes

Specific plastic glasses only

- Face protection: *Select an answer*

- Coat: *Select an answer*

A surgical mask outside the gross macroscopy room (office, etc.)

- *Paper work:*

- Did you keep on receiving on paper the clinical associated data transmitted with specimens?  Yes  No

- Was the information (including the status of the patient for COVID-19) transmitted in an electronic way?  Yes  No

- If yes, did you inform the patient that you used only an electronic way?  Yes  No

- *Detection of SARS-CoV-2 in patients in pulmonary and/or thoracic surgery departments:*

- Were patients undergoing thoracic surgery systematically tested (RT-PCR) for SARS-CoV-2 the day before?  Yes  No

- Were patients undergoing bronchoscopy (BAL, biopsy, bronchial aspirates, EBUS) or pleural puncture systematically tested (RT-PCR) for SARS-CoV-2 the day before?

Yes  No

- Did patients undergoing a transthoracic biopsy (+/-ROSE) systematically tested (RT-PCR) for SARS-CoV-2 the day before?  Yes  No

- Were only patients with symptoms (fever, cough, etc.) systematically tested (RT-PCR) for SARS-CoV-2 before surgery or bronchoscopy?  Yes  No








- Did all patients undergoing thoracic surgery have a CT scan the day before surgery?

Yes  No

- If one or several of the above procedures began later than the 15<sup>th</sup> of March, please clarify the date *provide the date*.

**II. Clinical pathology**

Please provide for comparison the number of patients for the period from the 15<sup>th</sup> of March 2019 to the 31<sup>st</sup> of May 2019 and for the period from the 15<sup>th</sup> of March 2020 to the 31<sup>st</sup> of May 2020 for:

- Frozen sections;	2020:	2019:
- Total surgical specimens from the thorax;	2020:	2019:
- Thoracic malignant tumours;	2020:	2019:
- Thoracic non malignant disease;	2020: 	2019:
- Bronchial biopsy;	2020 : 	2019 :
- Transthoracic biopsy;	2020: 	2019:
- BAL;	2020: 	2019:
- Bronchial aspirate;	2020: 	2019:
- Pleural puncture;	2020: 	2019:
- Autopsy;	2020: 	2019:

**III. Molecular pathology**

Please provide for comparison the number of patients for the period from the 15<sup>th</sup> of March 2019 to the 31<sup>st</sup> of May 2019 and for the period from the 15<sup>th</sup> of March 2020 to the 31<sup>st</sup> of May 2020 for:

- NGS tissue testing for routine;	2020:	2019:
- NGS tissue testing for clinical trial;	2020:	2019:
- Specific based PCR tissue testing;	2020:	2019:
-Liquid biopsy;	2020:	2019:
- FISH;	2020:	2019:

## IV. Biobanking

Please provide for comparison the number of patients for the period from the 15<sup>th</sup> of March 2019 to the 31<sup>st</sup> of May 2019 and for the period from the 15<sup>th</sup> of March 2020 to the 31<sup>st</sup> of May 2020 for:

- |                                     |       |       |
|-------------------------------------|-------|-------|
| - Frozen tissue;                    | 2020: | 2019: |
| - FFPE tissue blocks;               | 2020: | 2019: |
| - Blood specimen;                   | 2020: | 2019: |
| - Other specimens (please clarify); | 2020: | 2019: |

## V. Translational research activity related to COVID-19

- Did you develop or participate in a research project related to COVID-19 that used samples from positive COVID-19 patients?  No  Yes => with which samples:
- Did you perform autopsies on positive COVID-19 patients?  No  Yes => does your autopsy room have a BSL3 environment?  No  Yes
- Are you involved in different publications related to COVID-19?  
 No  Yes => how many :

## VI. Education and training

- Did you set up a training/educational program for biosafety procedures dedicated to COVID-19 in your laboratory?

- Documents
- Video
- Participation to webinars
- Not yet

- Did you keep going while training the residents during this period?  No  Yes => How?

## **VII. Impact of the COVID-19 pandemic on the organization of your pathology laboratory (15<sup>th</sup> of March-31<sup>st</sup> of May 2020)**

- What was the global percentage of your staff doing teleworking (and/or stay at home/and/ or participating in clinical department work) during this period?

- % among the pathologists?

- % among the technicians?

- % among the residents?

- % among other staff members?

## **VIII. Near organization in the pathology laboratory**

- According to you what will be the major impact of the COVID-19 pandemic on the future organization of your pathology laboratory:

- concerning the equipment (hoods; macroscopy room; autopsy room; etc.):

- concerning the PPE and biosafety procedures:

- concerning training and educational programs:

- concerning the research activity:

- others:

## **IX Status of staff members**

1. Total number of staff members:

2. Total number of staff members with fever:

3. Total number of staff members with another symptomatology (cough, thoracic pain, anosmia, ageusia, diarrhea):

4. Total number of pathologists with fever and/or a symptomatology:

5. Total number of technicians with fever and/or a symptomatology:

6. Total number of residents with fever and/or a symptomatology:

7. Total number of other staff members with fever and/or a symptomatology:

8. Total number of staff members tested by RT-PCR:
9. Total number of staff members positive after RT-PCR:
10. Total number of pathologists positive after RT-PCR:
11. Total number of technicians positive after RT-PCR:
12. Total number of resident positive after RT-PCR:
13. Total number of other staff members positive after RT-PCR:
14. Total number of staff members tested by serology:
15. Total number of pathologists positive after serology:
16. Total number of technicians positive after serology:
17. Total number of resident positive after serology:
18. Total number of other staff members positive after serology:
19. Total number of staff members in quarantine:
20. Total number of pathologists in quarantine:
21. Total number of technicians in quarantine:
22. Total number of residents in quarantine:
23. Total number of other staff members in quarantine:
24. Total number with identification of an external cause of contamination
25. Total number with identification of a work cause of contamination: